Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

Gilead sign

Gilead awaits EU decision on hep C combo treatment

December 8, 2015
Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir

The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …

News
Gilead image

EU approval for Gilead’s HIV combo Genvoya

December 1, 2015
Manufacturing and Production, Sales and Marketing European Commission, Genvoya, Gilead, Gilead Sciences, HIV, TDF, World Aids Day, european union, taf

Gilead Sciences has won marketing authorisation from the European Commission (EC) for the once-daily single tablet regimen Genvoya as an …

News
Gilead image

FDA expands Gilead’s Harvoni indications for Hep C

November 13, 2015
Sales and Marketing Gilead, Gilead Sciences, harvoni, ledipasvir-sofosbuvir

Gilead’s Harvoni has been approved by the FDA for expanded use in patients with genotypes 4, 5 and 6 chronic …

News

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
Truvada pill

Gilead’s Truvada prevents HIV infections in high-risk men

September 10, 2015
Research and Development Gilead, HIV, PrEP, Truvada, pre-exposure prophylaxis treatment, sexually transmitted infections

UK researchers say Truvada, Gilead’s HIV prevention treatment, should be added to the country’s ‘HIV prevention toolkit’, after a study …

News
Daklinza

NICE restricts access to new hepatitis C treatments

July 29, 2015
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C

NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …

News
FDA image

FDA sued over failure to disclose Sovaldi data

June 30, 2015
Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi

Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …

News
Sovaldi image

China rejects Gilead’s Sovaldi patent

June 24, 2015
Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi

Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …

News
Zydelig image

NICE wants more answers from Gilead on Zydelig

June 18, 2015
Sales and Marketing Gilead, MabThera, NICE, Roche, UK, brett wells, zydelig

The National Institute for Health and Care Excellence has not recommended Gilead’s leukaemia drug Zydelig in draft guidance.  But the …

News
Bayer image

Bayer and Gilead expand in manufacturing

June 2, 2015
Manufacturing and Production, Sales and Marketing Bayer, Gilead, brett wells, manufacturing

Both Bayer and Gilead are investing heavily into their manufacturing operations with expansion plans being laid down in Indonesia and …

News
gilead image

Gilead buys EpiTherapeutics for $65 million

May 7, 2015
Sales and Marketing EpiTherapeutics, Gilead

Gilead is clearly eyeing a future market involving epigenetics as the US firm buys Danish company EpiTherapeutics for $65 million. …

News
pillsphotos1

The Pharmafocus debate: Is the price of new hepatitis C treatments fair?

April 27, 2015
Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi

YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …

Feature
Gilead image

Gilead presents new Sovaldi data

April 23, 2015
Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi

Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …

News
Gilead image

Gilead’s next-generation HIV drug to be FDA assessed

April 8, 2015
Research and Development, Sales and Marketing F/TAF, FDA, Gilead, HIV, Tenofovir Alafenamide, emtricitabine

Gilead Sciences has filed its second new drug application for a new combination HIV treatment with the FDA.The California-based company …

News
Sovaldi image

$10 generic Solvaldi emerges in Bangladesh

March 10, 2015
Manufacturing and Production, Sales and Marketing Gilead, World Trade Organization, hep C, incepta, sofosbuvir, sofosbuvir), sovaldi

A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025